Skip to main content
Equibles
ALNY logo

ALNY · Alnylam Pharmaceuticals, Inc. · Metrics

Track ALNY — free

Use ALNY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALNY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$246.74 -7.33 (-2.89%) At close · Sep 30
Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$34.17B
Shares
133.81M
Volume · Sep 30 1.04M Avg daily vol (3M) 1.8M

ALNY metrics

71 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$246.74
Market cap
$34.17B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
+5.6%
Price change (3M)
-15.6%
Price change (6M)
-23.2%
Price change (YTD)
-36.1%
Price change (1Y)
-43.2%
Trailing year
Price change (5Y)
+43.2%
52-week high
$491.22
52-week low
$205.48
Change from 52-week high
-48.3%
Change from 52-week low
+23.6%
Annualized volatility
47.4%
Annualized volatility (3M)
72.3%
Beta
0.4
RSI (14D)
54.4
Price vs SMA 50
+4.3%
Price vs SMA 200
-16.8%
Avg volume (3M)
1.81M
Relative volume
0.4
Average dollar volume
$452.06M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
133.81M

Valuation

12 metrics
P / E (TTM)
44.1
Trailing earnings · reciprocal yield 2.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.1×
reciprocal yield 14.1%
P / book
25.2
reciprocal yield 4.0%
FCF yield
2.4%
TTM · current market cap
Buyback yield
—
P / FCF
41.7
reciprocal yield 2.4%
P / operating cash flow
37.5
reciprocal yield 2.7%
Earnings yield
2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
24.7×
reciprocal yield 4.0%
EV / revenue historical average (5Y)
24.7×
reciprocal yield 4.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
79.8%
Operating margin
20.8%
Trailing 12 months
Net margin
8.4%
Gross profit (TTM)
—
Operating profit (TTM)
$999.78M
Net income (TTM)
$774.71M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
17.1%
Effective tax rate
-1.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.96

Growth

11 metrics
Revenue growth YoY
+66.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.80B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.9%
Year over year · more shares
Revenue CAGR (3Y)
+53.0%
Revenue CAGR (5Y)
+49.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
57.2%
Return on assets
13.9%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
$1.05B
Free cash flow (TTM)
$819.87M
Quick ratio
3.0
Interest coverage
3.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.71B
Total assets
$5.56B
Total debt
$677.72M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$911.81M
Capital expenditures (TTM)
$91.95M
R&D (TTM)
$1.51B
SG&A (TTM)
$1.32B
Stock compensation (TTM)
$336.62M
R&D / revenue
31.4%
Stock compensation / revenue
7.0%

Ownership (13F)

3 metrics
13F filers
799
13F filer change QoQ
+1
Institutional ownership
101.3%

Short interest

3 metrics
Short interest
5.4%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1178670 CUSIP 02043Q107 13F (30d) 20 filings 16 filers Visit website Investor relations